February 2023
« Back to 2023
–
In Print
Friday, February 24, 2023
Matthew Herder and colleagues critically analyze the basis upon which Health Canada approved OxyContin.
Friday, February 24, 2023
In this posted letter, Matthew Herder explains his reasons for resigning from the Patented Prices Review Board on Mon. 20 Feb 2023.
–
In Print
Friday, February 24, 2023
Matthew Herder and colleagues critically review the regulatory history of buprenorphine formulations in Canada.
–
In Print
Thursday, February 23, 2023
Matthew Herder and colleagues publish on the topic of fair pricing and Canada's orphan drug policy.